DOI:10.1111/j.1365-2125.2005.02557.x

AUTHOR INDEX

AARONS, L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed: 581
ABBAS, A. *see* PAUL, G.A.
ABILDSTROM, S.Z. *see* RASMUSSEN, J.N.
ABRAMOWITZ, W. *see* JAKATE, A.S.
AFSHARI, R., GOOD, A.M., MAXWELL, S.R.J. & BATEMAN, D.N. Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics: 444
AGUILERA, C. *see* VALLANO, A.
AGUSTÍ, A. *see* VALLANO, A.
AKINO, M. *see* NONEN, S.
AKOVA, Y.A. *see* ALTAN-YAYCIOGLU, R.
ALLAVENA, C. *see* DAILLY, E.
ALLEN, M.B. *see* TOMLINSON, H.S.
ALLISON, M.J. *see* KOVARIK, J.M.
ALTAN-YAYCIOGLU, R., YAYCIOGLU, O. & AKOVA, Y.A. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: 669
ANDERSEN, M. *see* DYBDAHL, T.
ANDO, H. *see* TSURUOKA, S.
ANDO, H., TSURUOKA, S., YANAGIHARA, H., SUGIMOTO, K.-I., MIYATA, M., YAMAZOE, Y., TAKAMURA, T., KANEKO, S. & FUJIMURA, A. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin: 494
ANGEL, I. *see* ROSENBERG, G.
ANKRI, A. *see* SANCHEZ-PENA, P.
ANWAR, S. *see* BERGER, E.
AOSHIMA, T. *see* TOKAIRIN, T.
ARLET, P. *see* TAVASSOLI, N.
ARNAU, J.M. *see* VALLANO, A.
ARONSON, J.K. Metameta-analysis: 117
ARONSON, J.K. Monitoring therapy: 229
ARONSON, J.K. One hundred years of atrial fibrillation: 345
ARONSON, J.K. Prescribing statins: 457
ARONSON, J.K. Side-effects of Drugs Annual 27: 454
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BEGG, E.J. & BABER, N.S. Editors' report 2004: 5
AUMAIS, C. *see* SPÉNARD, J.
AZUMA, J. *see* NONEN, S.

BØGGILD, H. *see* THOMSEN, R.W.
BÄCKMAN, L. *see* BÖTTIGER, Y.
BABER, N.S. *see* ARONSON, J.K.
BACKMAN, J.T. *see* NIEMI, M.
BAE, J.-W., KIM, H.-K., KIM, J.-H., YANG, S.-I., KIM, M.-J., JANG, C.-G., PARK, Y.-S. & LEE, S.-Y. Allele and genotype frequencies of CYP2C9 in a Korean population: 418
BAGHERI, H. *see* TAVASSOLI, N.
BAS IN 'T VELD *see* STURKENBOOM, M.C.J.M.
BATEMAN, D.N. *see* AFSHARI, R.
BEALE, J. *see* WILCOCK, A.
BEDDING, A. *see* PATTERSON, D.
BEGG, E.J. *see* ARONSON, J.K.
BEIJNEN, J.H. *see* CROMMENTUYN, K.M.L.
BEIJNEN, J.H. *see* KAPPELHOFF, B.S.
BENKEMOUN, P. *see* TAVASSOLI, N.
BENNETT, K. *see* USHER, C.
BENOWITZ, N.L. *see* HUKKANEN, J.
BERGER, E., PATEL, K., ANWAR, S., DAVIES, W. & SHERIDAN, D.J. Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects: 17
BEYER, D. *see* KOVARIK, J.M.
BIZOT, M.N. *see* KOVARIK, J.M.
BLAIR, H.J. *see* DIDHAM, R.C.
BLOCH, M.T. *see* RAY, J.E.
BÖTTIGER, Y., BRATTSTRÖM, C., BÄCKMAN, L., CLAESSON, K. & BURKE, J.T. Trimethoprim–sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients: 566
BOCHNER, F. *see* HANNA, J.
BOLTON, A.E. *see* SCHMIDLI, H.
BONOVAS, S., FILIOUSSI, K. & SITARAS, N.M. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis: 194
BOOBIS, A.R. *see* PAUL, G.A.
BORTEY, E. *see* VAN DER POST, J.P.
BOUVY, M.L. *see* FABER, A.
BOWALGAHA, K., ELLIOT, D.J., MACKENZIE, P.I., KNIGHTS, K.M., SWEDMARK, S. & MINERS, J.O. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen: 423
BRAAT, S. *see* PATTERSON, D.
BRACCHI, R.C.G., HOUGHTON, J., WOODS, F.J., THOMAS, S., SMAIL, S.A. & ROUTLEDGE, P.A. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme: 221
BRATTSTRÖM, C. *see* BÖTTIGER, Y.
BROCKMÖLLER, J. *see* HOLSTEIN, A.
BROUWERS, J.R.B.J. *see* VAN ROON, E.N.
BROWN, H.S., ITO, K., GALETIN, A. & HOUSTON, J.B. Prediction of *in vivo* drug–drug interactions from *in vitro* data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant: 508
BRUNET, J.-S. *see* SPÉNARD, J.
BRUNNER, M., DEHGHANYAR, P., SEIGFRIED, B., MARTIN, W., MENKE, G. & MÜLLER, M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation: 573
BUCH, P. *see* RASMUSSEN, J.N.
BURAK, E.S. *see* VAN DER POST, J.P.
BURKE, J.T. *see* BÖTTIGER, Y.

CAPDEVILLE, R. *see* SCHMIDLI, H.
CEREZA, G. *see* VALLANO, A.
CEREZA, G., PEDRÓS, C., GARCIA, N. & LAPORTE, J.-R. Topiramate in non-approved indications and acute myopia or angle closure glaucoma: 578
CHAN, V., CHARLES, B.G. & TETT, S.E. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis: 257
CHARLES, B.G. *see* CHAN, V.
CHATELUT, E. *see* PUISSET, F.
CHEN, G.L. *see* LUO, C.-H.
CHEUNG, B.M.Y. *see* KUMANA, C.R.
CHEUNG, B.M.Y., WONG, Y.L. & LAU, C.P. Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996–2004: 90
CHEUNG, G.T.Y. *see* KUMANA, C.R.
CHEUNG, Y.B. *see* CHOWBAY, B.
CHIANG, M.Y. & SHAH, P. Nasal septal perforation enlargement related to topical ocular steroids: 578
CHIRKOV, Y.Y. *see* HOLMES, A.S.
CHOUSSAT, R. *see* SANCHEZ-PENA, P.
CHOWBAY, B., LI, H., DAVID, M., CHEUNG, Y.B. & LEE, E.J.D. Meta-analysis of the influence of *MDR1* C3435T polymorphism on digoxin pharmacokinetics and *MDR1* gene expression: 159

© 2005 Blackwell Publishing Ltd

DOI:10.1111/j.1365-2125.2005.02557.x

AUTHOR INDEX

AARONS, L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed: 581
ABBAS, A. *see* PAUL, G.A.
ABILDSTROM, S.Z. *see* RASMUSSEN, J.N.
ABRAMOWITZ, W. *see* JAKATE, A.S.
AFSHARI, R., GOOD, A.M., MAXWELL, S.R.J. & BATEMAN, D.N. Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics: 444
AGUILERA, C. *see* VALLANO, A.
AGUSTÍ, A. *see* VALLANO, A.
AKINO, M. *see* NONEN, S.
AKOVA, Y.A. *see* ALTAN-YAYCIOGLU, R.
ALLAVENA, C. *see* DAILLY, E.
ALLEN, M.B. *see* TOMLINSON, H.S.
ALLISON, M.J. *see* KOVARIK, J.M.
ALTAN-YAYCIOGLU, R., YAYCIOGLU, O. & AKOVA, Y.A. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: 669
ANDERSEN, M. *see* DYBDAHL, T.
ANDO, H. *see* TSURUOKA, S.
ANDO, H., TSURUOKA, S., YANAGIHARA, H., SUGIMOTO, K.-I., MIYATA, M., YAMAZOE, Y., TAKAMURA, T., KANEKO, S. & FUJIMURA, A. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin: 494
ANGEL, I. *see* ROSENBERG, G.
ANKRI, A. *see* SANCHEZ-PENA, P.
ANWAR, S. *see* BERGER, E.
AOSHIMA, T. *see* TOKAIRIN, T.
ARLET, P. *see* TAVASSOLI, N.
ARNAU, J.M. *see* VALLANO, A.
ARONSON, J.K. Metameta-analysis: 117
ARONSON, J.K. Monitoring therapy: 229
ARONSON, J.K. One hundred years of atrial fibrillation: 345
ARONSON, J.K. Prescribing statins: 457
ARONSON, J.K. Side-effects of Drugs Annual 27: 454
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BEGG, E.J. & BABER, N.S. Editors' report 2004: 5
AUMAIS, C. *see* SPÉNARD, J.
AZUMA, J. *see* NONEN, S.

BØGGILD, H. *see* THOMSEN, R.W.
BÄCKMAN, L. *see* BÖTTIGER, Y.
BABER, N.S. *see* ARONSON, J.K.
BACKMAN, J.T. *see* NIEMI, M.
BAE, J.-W., KIM, H.-K., KIM, J.-H., YANG, S.-I., KIM, M.-J., JANG, C.-G., PARK, Y.-S. & LEE, S.-Y. Allele and genotype frequencies of CYP2C9 in a Korean population: 418
BAGHERI, H. *see* TAVASSOLI, N.
BAS IN 'T VELD *see* STURKENBOOM, M.C.J.M.
BATEMAN, D.N. *see* AFSHARI, R.
BEALE, J. *see* WILCOCK, A.
BEDDING, A. *see* PATTERSON, D.
BEGG, E.J. *see* ARONSON, J.K.
BEIJNEN, J.H. *see* CROMMENTUYN, K.M.L.
BEIJNEN, J.H. *see* KAPPELHOFF, B.S.
BENKEMOUN, P. *see* TAVASSOLI, N.
BENNETT, K. *see* USHER, C.
BENOWITZ, N.L. *see* HUKKANEN, J.
BERGER, E., PATEL, K., ANWAR, S., DAVIES, W. & SHERIDAN, D.J. Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects: 17
BEYER, D. *see* KOVARIK, J.M.
BIZOT, M.N. *see* KOVARIK, J.M.
BLAIR, H.J. *see* DIDHAM, R.C.
BLOCH, M.T. *see* RAY, J.E.
BÖTTIGER, Y., BRATTSTRÖM, C., BÄCKMAN, L., CLAESSON, K. & BURKE, J.T. Trimethoprim–sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients: 566
BOCHNER, F. *see* HANNA, J.
BOLTON, A.E. *see* SCHMIDLI, H.
BONOVAS, S., FILIOUSSI, K. & SITARAS, N.M. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis: 194
BOOBIS, A.R. *see* PAUL, G.A.
BORTEY, E. *see* VAN DER POST, J.P.
BOUVY, M.L. *see* FABER, A.
BOWALGAHA, K., ELLIOT, D.J., MACKENZIE, P.I., KNIGHTS, K.M., SWEDMARK, S. & MINERS, J.O. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen: 423
BRAAT, S. *see* PATTERSON, D.
BRACCHI, R.C.G., HOUGHTON, J., WOODS, F.J., THOMAS, S., SMAIL, S.A. & ROUTLEDGE, P.A. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme: 221
BRATTSTRÖM, C. *see* BÖTTIGER, Y.
BROCKMÖLLER, J. *see* HOLSTEIN, A.
BROUWERS, J.R.B.J. *see* VAN ROON, E.N.
BROWN, H.S., ITO, K., GALETIN, A. & HOUSTON, J.B. Prediction of *in vivo* drug–drug interactions from *in vitro* data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant: 508
BRUNET, J.-S. *see* SPÉNARD, J.
BRUNNER, M., DEHGHANYAR, P., SEIGFRIED, B., MARTIN, W., MENKE, G. & MÜLLER, M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation: 573
BUCH, P. *see* RASMUSSEN, J.N.
BURAK, E.S. *see* VAN DER POST, J.P.
BURKE, J.T. *see* BÖTTIGER, Y.

CAPDEVILLE, R. *see* SCHMIDLI, H.
CEREZA, G. *see* VALLANO, A.
CEREZA, G., PEDRÓS, C., GARCIA, N. & LAPORTE, J.-R. Topiramate in non-approved indications and acute myopia or angle closure glaucoma: 578
CHAN, V., CHARLES, B.G. & TETT, S.E. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis: 257
CHARLES, B.G. *see* CHAN, V.
CHATELUT, E. *see* PUISSET, F.
CHEN, G.L. *see* LUO, C.-H.
CHEUNG, B.M.Y. *see* KUMANA, C.R.
CHEUNG, B.M.Y., WONG, Y.L. & LAU, C.P. Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the Hypertension Clinic 1996–2004: 90
CHEUNG, G.T.Y. *see* KUMANA, C.R.
CHEUNG, Y.B. *see* CHOWBAY, B.
CHIANG, M.Y. & SHAH, P. Nasal septal perforation enlargement related to topical ocular steroids: 578
CHIRKOV, Y.Y. *see* HOLMES, A.S.
CHOUSSAT, R. *see* SANCHEZ-PENA, P.
CHOWBAY, B., LI, H., DAVID, M., CHEUNG, Y.B. & LEE, E.J.D. Meta-analysis of the influence of *MDR1* C3435T polymorphism on digoxin pharmacokinetics and *MDR1* gene expression: 159

© 2005 Blackwell Publishing Ltd

CHRYSTYN, H. *see* TOMLINSON, H.S.
CIRAULO, D.A. & SHADER, R.I. Pharmacotherapy of Depression: 113
CLAESSON, K. *see* BÖTTIGER, Y.
COHEN, A.F. *see* VAN DER POST, J.P.
COHRS, S. *see* MEIER, A.
COLEMAN, J. *see* FERNER, R.E.
COLLET, J.-P. *see* SANCHEZ-PENA, P.
CONSTABLE, S.A. *see* FERNER, R.E.
CORLETT, S.A. *see* TOMLINSON, H.S.
CREMERS, S., SCHOEMAKER, R., SCHOLTEN, E., DEN HARTIGH, J., KÖNIG-QUARTEL, J., VAN KAN, E., PAUL, L. & DE FIJTER, J. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling: 249
CRESTEIL, T. *see* PUISSET, F.
CROMMENTUYN, K.M.L., KAPPELHOFF, B.S., MULDER, J.W., MAIRUHU, A.T.A., VAN GORP, E.C.M., MEENHORST, P.L., HUITEMA, A.D.R. & BEIJNEN, J.H. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients: 378
CULM-MERDEK, K.E., VON MOLTKE, L.L., HARMATZ, J.S. & GREENBLATT, D.J. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics: 486
CURRIE, G.P., PATERSON, E., KEENAN, F., NATH, S. & WATT, S.J. An unexpected response to intravenous hydrocortisone succinate in an asthmatic patient: 342

DAILLY, E., ALLAVENA, C., RAFFI, F. & JOLLIET, P. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz: 32
DALENC, F. *see* PUISSET, F.
DANÉS, I. *see* VALLANO, A.
DANSIRIKUL, C., DUFFULL, S.B., MORRIS1, R.G. & TETT, S.E. Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients: 560
DAVID, M. *see* CHOWBAY, B.
DAVIES, E.M. *see* SENBAGA, N.
DAVIES, W. *see* BERGER, E.
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE FIJTER, J. *see* CREMERS, S.
DE JONG, R.B. *see* STURKENBOOM, M.C.J.M.
DE JONG-VAN DEN BERG, L.T.W. *see* FABER, A.
DE KAM, M.L. *see* VAN DER POST, J.P.
DE VISSER, S.J. *see* VAN DER POST, J.P.
DÉMOLIS, J.-L., STRABACH, S., VACHERON, F. & FUNCK-BRENTANO, C. Assessment of the effect of a single oral dose of telithromycin on sotalol-induced QT interval prolongation in healthy women: 120
DEHGHANYAR, P. *see* BRUNNER, M.
DEMPSEY, D. *see* HUKKANEN, J.
DEN HARTIGH, J. *see* CREMERS, S.
DHAUN, N., STRACHAN, F.E., NEWBY, D.E., JOHNSTON, N.R., FORD, N.F., HAMMETT, J.L., PALMISANO, M. & WEBB, D.J. Vasodilator effects of the endothelin ET_A receptor selective antagonist BMS-193884 in healthy men: 611
DIDHAM, R.C., MCCONNELL, D.W., BLAIR, H.J. & REITH, D.M. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication: 519
DIELEMAN, J.P. *see* VAN DER HOOFT, C.S.
DIQUET, B. *see* PANHARD, X.
DRENTH, J.P.H. *see* VAN OIJEN, M.G.H.
DUAN, X.-H. *see* LUO, C.-H.
DUFFULL, S.B. *see* DANSIRIKUL, C.
DYBDAHL, T., ANDERSEN, M., KRAGSTRUP, J., KRISTIANSEN, I.S. & SØNDERGAARD, J. General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study: 526

EASTERBROOK, G. *see* LU, T.Y.-T.
EFFRON, M. *see* PATTERSON, D.
EGBERTS, E.-H. *see* HOLSTEIN, A.
EGBERTS, T.C.G. *see* FABER, A.
EISENBERG, E. *see* REZNIKOV, I.
EKINS-DAUKES, S., HELMS, P.J., TAYLOR, M.W. & MCLAY, J.S. Off-label prescribing to children: attitudes and experience of general practitioners: 145
EL-ATY, A.M.A. *see* LUO, C.-H.
EL-DIN, J. *see* HOLSTEIN, A.
ELLIOT, D.J. *see* BOWALGAHA, K.
EMMICK, J. *see* PATTERSON, D.
ENLUND, H. *see* HARTIKAINEN, S.

FABER, A., BOUVY, M.L., LOSKAMP, L., VAN DE BERG, P.B., EGBERTS, T.C.G. & DE JONG-VAN DEN BERG, L.T.W. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study: 641
FALANY, C.N., STRÖM, P. & SWEDMARK, S. Sulphation of o-desmethylnaproxen and related compounds by human cytosolic sulfotransferases: 632
FEELY, J. *see* USHER, C.
FERNER, R.E., COLEMAN, J., PIRMOHAMED, M., CONSTABLE, S.A. & ROUSE, A. The quality of information on monitoring for haematological adverse drug reactions: 448
FILIOUSSI, K. *see* BONOVAS, S.
FINN, G. *see* WILCOCK, A.
FINNSTRÖM, N. *see* THÖRN, M.
FOLINO-GALLO, P. *see* WALLEY, T.
FORD, N.F. *see* DHAUN, N.
FOSSEY, K. *see* WILCOCK, A.
FOSTER, D.J.R. *see* HANNA, J.
FRANSSEN, E.J.F. *see* VAN RIJ, C.M.
FRIBERG, J. *see* RASMUSSEN, J.N.
FRISBY, J. *see* WILCOCK, A.
FUJIMURA, A. *see* ANDO, H.
FUJIMURA, A. *see* TSURUOKA, S.
FUJIO, Y. *see* NONEN, S.
FUKASAWA, T. *see* TOKAIRIN, T.
FUNCK-BRENTANO, C. *see* DÉMOLIS, J.-L.

GALETIN, A. *see* BROWN, H.S.
GALITZ, L. *see* HOLMES, G.
GAN, L. *see* GREENBLATT, D.J.
GARCIA, N. *see* CEREZA, G.
GATHMANN, I. *see* SCHMIDLI, H.
GIBBS, J.S.R. *see* PAUL, G.A.
GISLASON, G.H. *see* RASMUSSEN, J.N.
GO, P.M.N.Y.H. *see* STURKENBOOM, M.C.J.M.
GOETTSCH, W.G. *see* STURKENBOOM, M.C.J.M.
GOOD, A.M. *see* AFSHARI, R.
GORDI, T., XIE, R. & JUSKO, W.J. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin: 594
GOUJARD, C. *see* PANHARD, X.
GRACE, M. *see* SPÉNARD, J.
GREENBLATT, D.J. *see* CULM-MERDEK, K.E.
GREENBLATT, D.J., GAN, L., HARMATZ, J.S. & SHADER, R.I. Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test: 244
GREUTER, H.N.J.M. *see* VAN RIJ, C.M.
GUSSACK *see* MORGANROTH
GUSTAFSSON, I. *see* RASMUSSEN, J.N.

HAMMETT, J.L. *see* DHAUN, N.
HANNA, J., FOSTER, D.J.R., SALTER, A., SOMOGYI, A.A., WHITE, J.M. & BOCHNER, F. Within- and between-subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects: 404

HARMATZ, J.S. *see* CULM-MERDEK, K.E.
HARMATZ, J.S. *see* GREENBLATT, D.J.
HARTIKAINEN, S., MÄNTYSELKÄ, P., LOUHIVUORI-LAAKO, K., ENLUND, H. & SULKAVA, R. Concomitant use of analgesics and psychotropics in home-dwelling elderly people – Kuopio 75 + study: 306
HELMS, P.J. *see* EKINS-DAUKES, S.
HENSLEY, M. *see* SCHMIDLI, H.
HERINGS, R.M.C. *see* STURKENBOOM, M.C.J.M.
HILT, D.C. *see* VAN DER POST, J.P.
HIRAO, Y. *see* ITO, S.
HIRAOKA, H., YAMAMOTO, K., MIYOSHI, S., MORITA, T., NAKAMURA, K., KADOI, Y., KUNIMOTO, F. & HORIUCHI, R. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain: 176
HOEKSTRA, M. *see* VAN ROON, E.N.
HOLMES, A.S., CHIRKOV, Y.Y., WILLOUGHBY, S.R., POROPAT, S., PEREIRA, J. & HOROWITZ, J.D. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance: 355
HOLMES, G., GALITZ, L., HU, P. & LYNESS, W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment: 469
HOLSTEIN, A., PLASCHKE, A., PTAK, M., EGBERTS, E.-H., EL-DIN, J., BROCKMÖLLER, J. & KIRCHHEINER, J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents: 103
HORAK, F., ZIEGLMAYER, P.U., ZIEGLMAYER, R., KAVINA, A. & LEMELL, P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration: 24
HORIUCHI, R. *see* HIRAOKA, H.
HOROWITZ, J.D. *see* HOLMES, A.S.
HOUGHTON, J. *see* BRACCHI, R.C.G.
HOUSTON, J.B. *see* BROWN, H.S.
HU, P. *see* HOLMES, G.
HUETHER, G. *see* MEIER, A.
HUITEMA, A.D.R. *see* CROMMENTUYN, K.M.L.
HUITEMA, A.D.R. *see* KAPPELHOFF, B.S.
HUITEMA, A.D.R. *see* VAN RIJ, C.M.
HUKKANEN, J., DEMPSEY, D., JACOB III, P. & BENOWITZ, N.L. Effect of pregnancy on a measure of FMO3 activity: 224
HULOT, J.-S. *see* SANCHEZ-PENA, P.
HUYBERS, S. *see* VAN OIJEN, M.G.H.
INADA, M. *see* ITO, S.
INOUE, Y. *see* ITO, S.
INOUE, Y. *see* TOKAIRIN, T.
IOKA, T. *see* TSURUOKA, S.
ITO, K. *see* BROWN, H.S.
ITO, S., KAWAMURA, T., INADA, M., INOUE, Y., HIRAO, Y., KOGA, T., KUNIZAKI, J.-I., SHIMIZU, T. & SATO, H. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using ^{13}C-uracil as an *in vivo* probe: 584

JACOB III, P. *see* HUKKANEN, J.
JAKATE, A.S., ROY, P., PATEL, A., ABRAMOWITZ, W., PERSIANI, S., WANGSA, J. & KAPIL, R. Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide: 498
JALONEN, J. *see* KORHONEN, T.
JANG, C.-G. *see* BAE, J.-W.
JANSEN, J.B.M.J. *see* VAN OIJEN, M.G.H.
JANSEN, T.L.T.A. *see* VAN ROON, E.N.
JIANG, Q. *see* KOVARIK, J.M.
JICK, H. *see* RUSSMANN, S.
JICK, S.S. *see* RUSSMANN, S.
JOHN, U. *see* MEISEL, P.
JOHNSEN, S.P. *see* THOMSEN, R.W.
JOHNSTON, N.R. *see* DHAUN, N.
JOLLIET, P. *see* DAILLY, E.
JORDAN, W. *see* MEIER, A.
JUNTTI-PATINEN, L. *see* NIEMI, M.
JUSKO, W.J. *see* GORDI, T.

KØBER, L. *see* RASMUSSEN, J.N.
KADOI, Y. *see* HIRAOKA, H.
KANEKO, S. *see* ANDO, H.
KAPIL, R. *see* JAKATE, A.S.
KAPPELHOFF, B.S. *see* CROMMENTUYN, K.M.L.
KAPPELHOFF, B.S., HUITEMA, A.D.R., SANKATSING, S.U.C., MEENHORST, P.L., VAN GORP, E.C.M., MULDER, J.W., PRINS, J.M. & BEIJNEN, J.H. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients: 276
KAVINA, A. *see* HORAK, F.
KAWAMURA, T. *see* ITO, S.
KAYE, J.A. *see* RUSSMANN, S.
KEELEY, V. *see* WILCOCK, A.
KEENAN, F. *see* CURRIE, G.P.
KIM, H.-K. *see* BAE, J.-W.
KIM, J.-H. *see* BAE, J.-W.
KIM, M.-J. *see* BAE, J.-W.
KIRCHHEINER, J. *see* HOLSTEIN, A.
KITABATAKE, A. *see* NONEN, S.
KLONER, R. *see* PATTERSON, D.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KNIGHTS, K.M. *see* BOWALGAHA, K.
KÖNIG-QUARTEL, J. *see* CREMERS, S.
KOCHER, T. *see* MEISEL, P.
KOGA, T. *see* ITO, S.
KORHONEN, T., TOLONEN, A., UUSITALO, J., LUNDGREN, S., JALONEN, J. & LAINE, K. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel: 69
KOVARIK, M.J., BEYER, D., BIZOT, M.N., JIANG, Q., ALLISON, M.J. & SCHMOUDER, R.L. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects: 434
KOZAK, A. *see* ROSENBERG, G.
KRAGSTRUP, J. *see* DYBDAHL, T.
KRISTIANSEN, I.S. *see* DYBDAHL, T.
KROEMER, H.K. *see* MEISEL, P.
KUMANA, C.R., CHEUNG, B.M.Y., CHEUNG, G.T.Y., OVEDAL, T., PEDERSON, B. & LAUDER, I.J. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat: 347
KUNIMOTO, F. *see* HIRAOKA, H.
KUNIZAKI, J.-I. *see* ITO, S.
KUPA, A. *see* LU, T.Y.-T.
KWONG, Y.Y.Y. *see* LEUNG, D.Y.L.

LAHEIJ, R.J.F. *see* VAN OIJEN, M.G.H.
LAINE, K. *see* KORHONEN, T.
LAITINEN, K. *see* LILJA, J.J.
LAM, D.S.C. *see* LEUNG, D.Y.L.
LAMMERTSMA, A.A. *see* VAN RIJ, C.M.
LAPORTE, J.-R. *see* CEREZA, G.
LAU, C.P. *see* CHEUNG, B.M.Y.
LAUDER, I.J. *see* KUMANA, C.R.
LAYTON, D. *see* PEARCE, H.M.
LECHAT, P. *see* SANCHEZ-PENA, P.
LEE, E.J.D. *see* CHOWBAY, B.
LEE, S.-Y. *see* BAE, J.-W.
LEFEBVRE, M. *see* SPÉNARD, J.
LEGRAND, M. *see* PANHARD, X.
LEMELL, P. *see* HORAK, F.
LENNARD, M.S. *see* ARONSON, J.K.
LENNARD, M.S. *see* WILCOCK, A.
LEUNG, D.Y.L., KWONG, Y.Y.Y. & LAM, D.S.C. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial: 668
LEWIS, L.D. Personalized medicine (or drug therapy); the patients' genome, the chip and the physician: 1
LI, H. *see* CHOWBAY, B.
LILJA, J.J., LAITINEN, K. & NEUVONEN, P.J. Effects of grapefruit juice on the absorption of levothyroxine: 337
LILJA, J.J., RAASKA, K. & NEUVONEN, P.J. Effects of grapefruit juice on the pharmacokinetics of acebutolol: 659
LIMSAKUN, T. *see* VAN DER POST, J.P.
LÖÖF, L. *see* THÖRN, M.
LOCHON, I. *see* PUISSET, F.
LOSKAMP, L. *see* FABER, A.

LOUHIVUORI-LAAKO, K. *see* HARTIKAINEN, S.
LU, T.Y.-T., KUPA, A., EASTERBROOK, G. & MANGONI, A.A. Profound weight loss associated with reboxetine use in a 44-year-old woman: 218
LUNDGREN, S. *see* KORHONEN, T.
LUNDGREN, S. *see* THÖRN, M.
LUO, C.-H., WANG, A., ZHU, R.-H., ZHANG, W.-X., MO, W., YU, B.-N., CHEN, G.L., OU-YANG, D.-S., DUAN, X.-H., EL-ATY, A.M.A. & ZHOU, H.-H. Gender specific association of *CYP2C9*3* with hyperlipidaemia in Chinese: 629
LYNESS, W. *see* HOLMES, G.

MÄNTYSELKÄ, P. *see* HARTIKAINEN, S.
MACDONALD, T. *see* PATTERSON, D.
MACKENZIE, P.I. *see* BOWALGAHA, K.
MACLEOD, M.J. *see* ROSS, S.
MADSEN, M. *see* RASMUSSEN, J.N.
MAIRUHU, A.T.A. *see* CROMMENTUYN, K.M.L.
MALLING, D., POULSEN, M.N. & SØGAARD, B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects: 287
MANGONI, A.A. *see* LU, T.Y.-T.
MANTEL-TEEUWISSE, A.K., KLUNGEL, O.H., SCHALEKAMP, T., VERSCHUREN, W.M.M., PORSIUS, A.J. & DE BOER, A. Suboptimal choices and dosing of statins at start of therapy: 83
MARRIOTT, D. *see* RAY, J.E.
MARTIN, W. *see* BRUNNER, M.
MASSICOTTE, J. *see* SPÉNARD, J.
MATSUI, Y. *see* NONEN, S.
MAXWELL, S.R.J. *see* AFSHARI, R.
MCCONNELL, D.W. *see* DIDHAM, R.C.
MCELNAY, J.C. *see* SADIK, A.
MCGOWAN, B. *see* USHER, C.
MCLACHLAN, A.J. *see* RAY, J.E.
MCLAY, J.S. *see* EKINS-DAUKES, S.
MEENHORST, P.L. *see* CROMMENTUYN, K.M.L.
MEENHORST, P.L. *see* KAPPELHOFF, B.S.
MEIER, A., NEUMANN, A.-C., JORDAN, W., HUETHER, G., RODENBECK, A., RÜTHER, E. & COHRS, S. Ziprasidone decreases cortisol excretion in healthy subjects: 330
MEISEL, P., SCHWAHN, C., JOHN, U., KROEMER, H.K. & KOCHER, T. Calcium antagonists and deep gingival pockets in the population-based SHIP study: 552
MENKE, G. *see* BRUNNER, M.
MENTRÉ, F. *see* PANHARD, X.
MINERS, J.O. *see* BOWALGAHA, K.
MITCHELL, M. *see* PATTERSON, D.
MIURA, M., TADA, H., YASUI-FURUKORI, N., UNO, T., SUGAWARA, K., TATEISHI, T. & SUZUKI, T. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine: 61
MIYATA, M. *see* ANDO, H.
MIYOSHI, S. *see* HIRAOKA, H.
MO, W. *see* LUO, C.-H.
MOENS, H.J.B. *see* VAN ROON, E.N.
MONTALESCOT, G. *see* SANCHEZ-PENA, P.
MONTASTRUC, J.-L. *see* TAVASSOLI, N.
MORGANROTH & GUSSACK Cardiac safety of noncardiac drugs: 227
MORITA, T. *see* HIRAOKA, H.
MORRIS1, R.G. *see* DANSIRIKUL, C.
MORTENSEN, J.T. *see* THOMSEN, R.W.
MÜLLER, M. *see* BRUNNER, M.
MULDER, J.W. *see* CROMMENTUYN, K.M.L.
MULDER, J.W. *see* KAPPELHOFF, B.S.
MULLA1, H. & POOBONI, S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation: 265

NAKAMURA, K. *see* HIRAOKA, H.
NAMUSHI, R.N. *see* SARAVANAN, N.
NATH, S. *see* CURRIE, G.P.
NEUMANN, A.-C. *see* MEIER, A.
NEUVONEN, M. *see* NIEMI, M.
NEUVONEN, P.J. *see* LILJA, J.J.
NEUVONEN, P.J. *see* NIEMI, M.
NEWBY, D.E. *see* DHAUN, N.
NIEMI, M., BACKMAN, J.T., JUNTTI-PATINEN, L., NEUVONEN, M. & NEUVONEN, P.J. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide: 208
NONEN, S., OKAMOTO, H., AKINO, M., MATSUI, Y., FUJIO, Y., YOSHIYAMA, M., TAKEMOTO, Y., YOSHIKAWA, J., AZUMA, J. & KITABATAKE, A. No positive association between adrenergic receptor variants of α_{2C}Del322–325, β_1Ser49, β_1Arg389 and the risk for heart failure in the Japanese population: 414

O'SHAUGHNESSY, K.M. *see* SANDILANDS, A.J.
OKAMOTO, H. *see* NONEN, S.
OLESEN, A.V. *see* THOMSEN, R.W.
OLSEN, J. *see* THOMSEN, R.W.
OTAIKU, O.M. *see* SARAVANAN, N.
OTANI, K. *see* TOKAIRIN, T.
OU-YANG, D.-S. *see* LUO, C.-H.
OVEDAL, T. *see* KUMANA, C.R.

PALMISANO, M. *see* DHAUN, N.
PANHARD, X., GOUJARD, C., LEGRAND, M., TABURET, A.M., DIQUET, B., MENTRÉ, F. & THE COPHAR 1-ANRS STUDY GROUP. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART: 390
PARK, Y.-S. *see* BAE, J.-W.
PASSIER, A. & VAN PUIJENBROEK, E. Mirtazapine-induced arthralgia: 570
PATEL, A. *see* JAKATE, A.S.
PATEL, K. *see* BERGER, E.
PATERSON, E. *see* CURRIE, G.P.
PATTERSON, D., KLONER, R., EFFRON, M., EMMICK, J., BEDDING, A., WARNER, M., MITCHELL, M., BRAAT, S. & MACDONALD, T. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease: 459
PAUL, G.A., GIBBS, J.S.R., BOOBIS, A.R., ABBAS, A. & WILKINS, M.R. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension: 107
PAUL, L. *see* CREMERS, S.
PEARCE, H.M., LAYTON, D., WILTON, L.V. & SHAKIR, S.A.W. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin®: 98
PEDERSON, B. *see* KUMANA, C.R.
PEDROÓS, C. *see* CEREZA, G.
PEDRÒS, C. *see* VALLANO, A.
PENG, B. *see* SCHMIDLI, H.
PEREIRA, J. *see* HOLMES, A.S.
PERSIANI, S. *see* JAKATE, A.S.
PETERS, W.H.M. *see* VAN OIJEN, M.G.H.
PICELLI, G. *see* STURKENBOOM, M.C.J.M.
PIRMOHAMED, M. *see* FERNER, R.E.
PLASCHKE, A. *see* HOLSTEIN, A.
POOBONI, S. *see* MULLA1, H.
POROPAT, S. *see* HOLMES, A.S.
PORSIUS, A.J. *see* MANTEL-TEEUWISSE, A.K.
POULSEN, M.N. *see* MALLING, D.
PRINS, J.M. *see* KAPPELHOFF, B.S.
PTAK, M. *see* HOLSTEIN, A.
PUD, D. *see* REZNIKOV, I.
PUISSET, F., DALENC, F., CHATELUT, E., CRESTEIL, T., LOCHON, I., TISNES, P. & ROCHÉ, H. Dexamethasone as a probe for vinorelbine clearance: 45

RAASKA, K. *see* LILJA, J.J.
RACINE-POON, A. *see* SCHMIDLI, H.
RAFFI, F. *see* DAILLY, E.
RANE, A. *see* THÖRN, M.
RASMUSSEN, J.N., GISLASON, G.H., ABILDSTROM, S.Z., RASMUSSEN, S., GUSTAFSSON, I., BUCH, P., FRIBERG, J., KØBER, L., TORP-PEDERSEN, C., MADSEN, M. &

STENDER, S. Statin use after acute myocardial infarction: a nationwide study in Denmark: 150
RASMUSSEN, S. *see* RASMUSSEN, J.N.
RAY, J.E., MARRIOTT, D., BLOCH, M.T. & MCLACHLAN, A.J. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic: 291
REITH, D.M. *see* DIDHAM, R.C.
REZNIKOV, I., PUD, D. & EISENBERG, E. Oral opioid administration and hyperalgesia in patients with cancer or chronic nonmalignant pain: 311
RITTER, J.M. *see* ARONSON, J.K.
RIVIERE, G.-J. *see* SCHMIDLI, H.
ROCHÉ, H. *see* PUISSET, F.
RODENBECK, A. *see* MEIER, A.
ROSENBERG, G., ANGEL, I. & KOZAK, A. Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans: 7
ROSS, S. & MACLEOD, M.J. Antihypertensive drug prescribing in grampian: 300
ROUSE, A. *see* FERNER, R.E.
ROUTLEDGE, P.A. *see* BRACCHI, R.C.G.
ROY, P. *see* JAKATE, A.S.
RÜTHER, E. *see* MEIER, A.
RUSSMANN, S., KAYE, J.A., JICK, S.S. & JICK, H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database: 76

SØGAARD, B. *see* MALLING, D.
SØNDERGAARD, J. *see* DYBDAHL, T.
SØRENSEN, H.T. *see* THOMSEN, R.W.
SADIK, A., YOUSIF, M. & MCELNAY, J.C. Pharmaceutical care of patients with heart failure: 183
SAILLER, L. *see* TAVASSOLI, N.
SALTER, A. *see* HANNA, J.
SANCHEZ-PENA, P., HULOT, J.-S., URIEN, S., ANKRI, A., COLLET, J.-P., CHOUSSAT, R., LECHAT, P. & MONTALESCOT, G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis: 364
SANDILANDS, A.J. & O'SHAUGHNESSY, K.M. The functional significance of genetic variation within the β_1-adrenoceptor: 235
SANKATSING, S.U.C. *see* KAPPELHOFF, B.S.
SARAVANAN, N., OTAIKU, O.M. & NAMUSHI, R.N. Interstitial pneumonitis during lamotrigine therapy: 666
SATO, H. *see* ITO, S.
SCHACHTER, M. Changes in the usage of antihypertensive drugs: implications and prospects: 231
SCHALEKAMP, T. *see* MANTEL-TEEUWISSE, A.K.
SCHMIDLI, H., PENG, B., RIVIERE, G.-J., CAPDEVILLE, R., HENSLEY, M., GATHMANN, I., BOLTON, A.E. & RACINE-POON, A. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study: 35
SCHMOUDER, R.L. *see* KOVARIK, J.M.
SCHOEMAKER, R. *see* CREMERS, S.
SCHOLTEN, E. *see* CREMERS, S.
SCHWAHN, C. *see* MEISEL, P.
SEIGFRIED, B. *see* BRUNNER, M.
SENBAGA, N. & DAVIES, E.M. Inadvertent intrathecal administration of rifampicin: 116
SHADER, R.I. *see* CIRAULO, D.A.
SHADER, R.I. *see* GREENBLATT, D.J.
SHAH, P. *see* CHIANG, M.Y.
SHAKIR, S.A.W. *see* PEARCE, H.M.
SHERIDAN, D.J. *see* BERGER, E.
SHIMIZU, T. *see* ITO, S.
SITARAS, N.M. *see* BONOVAS, S.
SLUSHER, B.S. *see* VAN DER POST, J.P.
SMAIL, S.A. *see* BRACCHI, R.C.G.
SOMOGYI, A.A. *see* HANNA, J.
SPÉNARD, J., AUMAIS, C., MASSICOTTE, J., BRUNET, J.-S., TREMBLAY, C., GRACE, M. & LEFEBVRE, M. Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter *pylori* eradication: 374
STENDER, S. *see* RASMUSSEN, J.N.
STEPHENS, P. *see* WALLEY, T.
STRABACH, S. *see* DÉMOLIS, J.-L.
STRACHAN, F.E. *see* DHAUN, N.
STRICKER, B.H.CH. *see* VAN DER HOOFT, C.S.
STRÖM, P. *see* FALANY, C.N.
STURKENBOOM, M.C.J.M. *see* VAN DER HOOFT, C.S.
STURKENBOOM, M.C.J.M., GOETTSCH, W.G., PICELLI, G., BAS IN 'T VELD, YIN, D.D., DE JONG, R.B., GO, P.M.N.Y.H. & HERINGS, R.M.C. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs: 438
SUGAWARA, K. *see* MIURA, M.
SUGIMOTO, K. *see* TSURUOKA, S.
SUGIMOTO, K.-I. *see* ANDO, H.
SULKAVA, R. *see* HARTIKAINEN, S.
SUZUKI, A. *see* TOKAIRIN, T.
SUZUKI, T. *see* MIURA, M.
SWART, E.L. *see* VAN RIJ, C.M.
SWEDMARK, S. *see* BOWALGAHA, K.
SWEDMARK, S. *see* FALANY, C.N.

'T JONG, G.W. *see* VAN DER HOOFT, C.S.

TABURET, A.M. *see* PANHARD, X.
TADA, H. *see* MIURA, M.
TAKAMURA, T. *see* ANDO, H.
TAKEMOTO, Y. *see* NONEN, S.
TATEISHI, T. *see* MIURA, M.
TATEISHI, T. *see* TOKAIRIN, T.
TAVASSOLI, N., BAGHERI, H., SAILLER, L., BENKEMOUN, P., MONTASTRUC, J.-L. & ARLET, P. Estimation of time devoted to adverse drug reactions assessment in an internal medicine department: 452
TAYLOR, M.W. *see* EKINS-DAUKES, S.
TEELING, M. *see* USHER, C.
TETT, S.E. *see* CHAN, V.
TETT, S.E. *see* DANSIRIKUL, C.
THE COPHAR 1-ANRS STUDY GROUP. *see* PANHARD, X
THÖRN, M., FINNSTRÖM, N., LUNDGREN, S., RANE, A. & LÖÖF, L. Cytochromes P450 and *MDR1* mRNA expression along the human gastrointestinal tract: 54
THOMAS, J. *see* WILCOCK, A.
THOMAS, S. *see* BRACCHI, R.C.G.
THOMSEN, R.W., JOHNSEN, S.P., OLESEN, A.V., MORTENSEN, J.T., BØGGILD, H., OLSEN, J. & SØRENSEN, H.T. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study: 534
TISNES, P. *see* PUISSET, F.
TOBI, H. *see* VAN ROON, E.N.
TOKAIRIN, T., FUKASAWA, T., YASUI-FURUKORI, N., AOSHIMA, T., SUZUKI, A., INOUE, Y., TATEISHI, T. & OTANI, K. Inhibition of the metabolism of brotizolam by erythromycin in humans: *in vivo* evidence for the involvement of CYP3A4 in brotizolam metabolism: 172
TOLONEN, A. *see* KORHONEN, T.
TOMLINSON, H.S., CORLETT, S.A., ALLEN, M.B. & CHRYSTYN, H. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge: 605
TORP-PEDERSEN, C. *see* RASMUSSEN, J.N.
TREMBLAY, C. *see* SPÉNARD, J.
TSURUOKA, S. *see* ANDO, H.
TSURUOKA, S., WAKAUMI, M., IOKA, T., YAMAMOTO, H., ANDO, H., SUGIMOTO, K. & FUJIMURA, A. Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan: 204

UNO, T. *see* MIURA, M.
URIEN, S. *see* SANCHEZ-PENA, P.
USHER, C., TEELING, M., BENNETT, K., MCGOWAN, B. & FEELY, J. Usage of

paracetamol-containing combination analgesics remains high in primary care: 648
UUSITALO, J. *see* KORHONEN, T.

VACHERON, F. *see* DÉMOLIS, J.-L.
VALLANO, A., CEREZA, G., PEDRÒS, C., AGUSTÍFI, A., DANÉS, I., AGUILERA, C. & ARNAU, J.M. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital: 653
VAN DE BERG, P.B. *see* FABER, A.
VAN DE LAAR, M.A.F.J. *see* VAN ROON, E.N.
VAN DER CAMMEN, T.J.M. *see* VAN DER HOOFT, C.S.
VAN DER HOOFT, C.S., 'T JONG, G.W., DIELEMAN, J.P., VERHAMME, K.M.C., VAN DER CAMMEN, T.J.M., STRICKER, B.H.CH. & STURKENBOOM, M.C.J.M. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria – a population-based cohort study: 137
VAN DER POST, J.P., DE VISSER, S.J., DE KAM, M.L., WOELFLER, M., HILT, D.C., VORNOV, J., BURAK, E.S., BORTEY, E., SLUSHER, B.S., LIMSAKUN, T., COHEN, A.F. & VAN GERVEN, J.M.A. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693: 128
VAN GANSE, E. ON BEHALF OF THE EUROMEDSTAT GROUP *see* WALLEY, T.
VAN GERVEN, J.M.A. *see* VAN DER POST, J.P.
VAN GORP, E.C.M. *see* CROMMENTUYN, K.M.L.
VAN GORP, E.C.M. *see* KAPPELHOFF, B.S.
VAN KAN, E. *see* CREMERS, S.
VAN LOENEN, A.C. *see* VAN RIJ, C.M.
VAN OIJEN, M.G.H., HUYBERS, S., PETERS, W.H.M., DRENTH, J.P.H., LAHEIJ, R.J.F., VERHEUGT, F.W.A. & JANSEN, J.B.M.J. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid: 623
VAN PUIJENBROEK, E. *see* PASSIER, A.
VAN RIJ, C.M., HUITEMA, A.D.R., SWART, E.L., GREUTER, H.N.J.M., LAMMERTSMA, A.A., VAN LOENEN, A.C. & FRANSSEN, E.J.F. Population plasma pharmacokinetics of ^{11}C-flumazenil at tracer concentrations: 477
VAN ROON, E.N., HOEKSTRA, M., TOBI, H., JANSEN, T.L.T.A., MOENS, H.J.B., BROUWERS, J.R.B.J. & VAN DE LAAR, M.A.F.J. Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation: 319
VERHAMME, K.M.C. *see* VAN DER HOOFT, C.S.
VERHEUGT, F.W.A. *see* VAN OIJEN, M.G.H.
VERSCHUREN, W.M.M. *see* MANTEL-TEEUWISSE, A.K.
VON MOLTKE, L.L. *see* CULM-MERDEK, K.E.
VORNOV, J. *see* VAN DER POST, J.P.

WAKAUMI, M. *see* TSURUOKA, S.
WALLEY, T., FOLINO-GALLO, P., STEPHENS, P. & E. VAN GANSE ON BEHALF OF THE EUROMEDSTAT GROUP. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003: 543
WANG, A. *see* LUO, C.-H.
WANGSA, J. *see* JAKATE, A.S.
WARNER, M. *see* PATTERSON, D.
WATT, S.J. *see* CURRIE, G.P.
WEBB, D.J. *see* DHAUN, N.
WEBSTER, M. *see* WILCOCK, A.
WEE, B. *see* WILCOCK, A.
WHITE, J.M. *see* HANNA, J.
WILCOCK, A., THOMAS, J., FRISBY, J., WEBSTER, M., KEELEY, V., FINN, G., FOSSEY, K., WEE, B., BEALE, J. & LENNARD, M.S. Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit: 326
WILKINS, M.R. *see* PAUL, G.A.
WILLOUGHBY, S.R. *see* HOLMES, A.S.
WILTON, L.V. *see* PEARCE, H.M.
WOELFLER, M. *see* VAN DER POST, J.P.
WONG, Y.L. *see* CHEUNG, B.M.Y.
WOODS, F.J. *see* BRACCHI, R.C.G.

XIE, R. *see* GORDI, T.

YAMAMOTO, H. *see* TSURUOKA, S.
YAMAMOTO, K. *see* HIRAOKA, H.
YAMAZOE, Y. *see* ANDO, H.
YANAGIHARA, H. *see* ANDO, H.
YANG, S.-I. *see* BAE, J.-W.
YASUI-FURUKORI, N. *see* MIURA, M.
YASUI-FURUKORI, N. *see* TOKAIRIN, T.
YAYCIOGLU, O. *see* ALTAN-YAYCIOGLU, R.
YIN, D.D. *see* STURKENBOOM, M.C.J.M.
YOSHIKAWA, J. *see* NONEN, S.
YOSHIYAMA, M. *see* NONEN, S.
YOUSIF, M. *see* SADIK, A.
YU, B.-N. *see* LUO, C.-H.

ZHANG, W.-X. *see* LUO, C.-H.
ZHOU, H.-H. *see* LUO, C.-H.
ZHU, R.-H. *see* LUO, C.-H.
ZIEGLMAYER, P.U. *see* HORAK, F.
ZIEGLMAYER, R. *see* HORAK, F.

DOI:10.1111/j.1365-2125.2005.02558.x

SUBJECT INDEX

This index was compiled from the keywords

β-blocker, 90
13C-, 584
3-keto-desogestrel, 69
5HT1-receptors, 570
A77 1726, 257
acebutolol, 659
acetylsalicylic acid, 623
acute myocardial infarction, 150
adrenergic receptor, 414
adverse drug reaction, 570, 653
adverse drug reaction reporting systems, 653
adverse drug reactions, 218, 221
adverse effects, 552
adverse reactions, 204
allele, 418
analgesia, 311
analgesics, 306, 444
angioplasty, 364
angiotensin-converting enzyme inhibitor, 90
angiotensin-II receptor blockers, 204
antagonist, 611
anticoagulants, 364
antihistamine, 24
anti-hypertensives, 300
antipsychotics, 330
artemisinin, 594
arthralgia, 570
aspirin, 194
atazanavir, 291
atorvastatin, 494
Atrial fibrillation, 347
attitude, 145, 653
augmentation index, 355
Autonomic tone, 17

BAPTA, 7
Beers criteria, 137
benzodiazepines, 244
bioavailability, 374, 659
bismuth, 374
bolus insulin, 469
brain, 176
bronchoprovocation, 605
brotizolam, 172

calcium, 7
calcium antagonists, 552
calcium channel blocker, 90
Cancer, 326
cardiovascular disease, 623
central nervous system, 128
chelator, 7
child, 145
cholestasis, 76
chronic heart failure, 414
chronic myeloid leukaemia, 35
clinical pharmacy, 183
communication barriers, 653
concentration–effect, 560
concentration-response, 257
co-proxamol, 444
cortisol, 330
costs, 438
CYP2C19, 61, 287
CYP2C9, 103, 208, 418, 508, 623, 629
CYP2D6, 287, 508
CYP3A4, 172, 208, 494, 508
cytochrome P450, 54, 103, 326
cytochrome P450 (CYP) enzyme, 69
cytochrome P450 3A4/5, 45

death, 444
dermal penetration, 573
desmethylnaproxen, 423
desogestrel, 69
dexamethasone, 45
dexloxiglumide, 498
dextropropoxyphene, 444
diclofenac, 573
diffusion of innovation, 526
digoxin, 159
dihydropyrimidine dehydrogenase (DPD), 584
dose adjustment, 469
DP-b99, 7
drug combination, 374
drug interaction, 69, 208, 434, 494, 566
drug interactions, 120, 287, 326
drug metabolism, 54, 632
drug prescription, 150
drug survival, 319
drug therapy, 35, 448
drug utilization, 641, 90, 526
drug–drug interaction study, 498
drug–drug interactions, 508
drugs, 326
dysgeusia, 204

efavirenz, 32
elderly, 137, 306
Electrocardiography, 120
electroencephalography, 244
enantiomer, 61
enantiomers, 287, 404
endothelin, 611
endothelin antagonist, 107
enoxaparin, 364
enterohepatic cycle, 249
epidemiology, 150, 194, 438
erythromycin, 172
escitalopram, 287
ET_A receptor, 611
everolimus, 434
exercise induced ischaemia, 459

fexofenadine, 24
flucloxacillin, 76
fluconazole, 498
fluvoxamine, 61
food, 374
food-drug interaction, 337
food–drug interaction, 659
functional gastrointestinal disorders, 498

gemfibrozil, 208
gender, 629
general practice, 526, 648
general practitioners, 221
genotype, 418
gingival hyperplasia, 552
GI-tract, 54
GPRD, 76
grapefruit juice, 337, 494, 659
GTN, 17
gustometry, 204

haematological diseases, 448
haematological outcomes, 560
health outcomes, 183
Heart Failure, 183
HIV, 276, 291, 378
HMG-CoA reductase inhibitors, 494
hormone replacement therapy, 641
hospital, 653
HPA-axis, 330
human drug glucuronidation, 423
hyperlipidaemia, 629
hypertension, 90, 300
hypoglycaemia, 103

imatinib mesylate, 35
in vitro prediction, 508
inappropriate prescribing, 137
inappropriate use, 648
indinovir, 276
inhalation methods, 605
insulin analogues, 469
interaction, 32
interactions, 83
intra-abdominal infection, 438
ischaemia, 7
itraconazole, 208

Japanese, 414
joint model, 390

ketoconazole, 498
kidney transplantation, 249

© 2005 Blackwell Publishing Ltd

kidneys, 176
Korean, 418

lansoprazole, 61
leflunomide, 257, 319
leukaemia, 35
levocetirizine, 24
levothyroxine, 337
liver disease, 76
Long QT Syndrome, 120
lopinavir, 32
lopinavir/ritonavir, 378
lungs, 176

MDR1 C3435T polymorphism, 159
mechanism-based model, 594
medicines regulation, 448
meta-analysis, 159, 194, 347
metabolism, 69, 172, 176, 249, 287
metabolite, 390
methadone, 404
metronidazole, 374
microdialysis, 573
Mirtazapine, 570
modelling, 249
monitoring, 448
mycophenolic acid, 249

NAALAD-ase-inhibitor, 128
naphthol, 632
Naproxen, 632
nateglinide, 208
nelfinavir, 390
new drugs, 526
nitrate, 459
nitrates, 355
NNT, 347
nociception, 311
NONMEM, 257
nonmem, 364
nonsteroidal anti-inflammatory drugs, 194

off-label prescribing, 145
opioids, 311
oral antidiabetic, 103
oral contraceptives postmarketing, 98
ovarian cancer, 194
overdose, 444
oxytetracycline, 76

pain threshold, 311
pain, 311
palliative care, 326
paracetamol-containing analgesics, 648
P-glycoprotein, 45
pharmaceutical care, 183
pharmacists. distance learning, 221
pharmacodynamics, 244, 404, 560, 594
pharmacoepidemiology, 300, 534
pharmacokinetics, 32, 35, 107, 128, 159, 244, 249, 291, 364, 404, 498
pharmacokinetics, 594
pharmacotherapy, 83
pharmacovigilance, 653
phosphodiesterase 5 inhibitors, 459
Phosphodiesterase inhibitor, 107
physiologically based pharmacokinetic (PBPK) model, 584
pitavastatin, 494
platelets, 355
polymorphism, 103, 414
population pharmacokinetics, 45, 257, 276, 378, 390
population-based, 137
population-based cohort study, 76
predictors, 319
prescribing, 526, 641
prescription database, 648
prevention and control, 448
primary health care, 145
product surveillance, 98
Propofol, 176
psychotropics, 306

QT interval, 120
QTc intervals, 17
quality, 83

rate control, 347
RCT, 183
Reboxetine, 218
rheumatoid arthritis, 257, 319
rhythm control, 347
risk, 641
ritonavir, 276

salbutamol, 605
SAR, 24
seasonal allergic rhinitis, 24
secondary prevention, 150
serotonin, 570
serum creatinine, 566
sirolimus, 560, 566
smoking, 552
S-naproxen, 423
socioeconomic status, 534
Sotalol, 120
spontaneous reporting, 221
spray gel, 573
starting dose, 469
statins, 83, 150, 534
stroke, 7
sulfotransferase, 632
sulphation, 632

tadalafil, 459
Telithromycin, 120
tetracycline, 374
therapeutic drug monitoring, 291
thiazide diuretic, 90
topical, 573
toxicity, 291
treatment failure, 438
Triazolam, 244
trimethoprim–sulphamethoxazole, 566

UDP-glucuronosyltransferase, 423
UGT1A6, 623
UGT2B7, 423
upper gastrointestinal symptoms, 623
uracil, 584
urinary excretion, 330, 605

vasodilator, 17, 611
VCC, 24
venous thrombosis, 98
verapamil, 434
vinorelbine, 45

weight loss, 218
within and between subject variability, 404

yellow card scheme, 221

ziprasidone, 330